Literature DB >> 9798812

The effectiveness of cost-effectiveness analysis in containing costs.

N A Azimi1, H G Welch.   

Abstract

OBJECTIVE: Although cost-effectiveness analyses (CEAs) have been advocated as a tool to critically appraise the value of health expenditures, it has been widely hoped that they might also help contain health care costs. To determine how often they discourage additional expenditures, we reviewed the conclusions of recently published CEAs. DATA SOURCES: A search of the Abridged Index Medicus (a subset of MEDLINE designed to afford rapid access to the literature of "immediate interest" to the practicing physician) between 1990 and 1996. STUDY SELECTION: We only included articles that reported an explicit cost-effectiveness (CE) ratio (a cost for some given health effect) in the abstract. DATA ABSTRACTION: From each abstract, we collected the value for the incremental CE ratio and the measure of health effect (life-years, quality-adjusted life-years [QALYs], other). We then categorized the authors' conclusion into one of three categories: supports strategy requiring additional expenditure, no firm conclusion, and supports low-cost alternative. Finally, we obtained the article and collected information on funding source. DATA SYNTHESIS: Among the 109 eligible articles, the authors' conclusion supported strategies requiring additional expenditure in 58 (53%) and supported the low-cost alternative in 28 (26%). We then focused on the 65 articles reporting either life-years or QALYs. Cost-effectiveness ratios ranged from $400 to $166,000 (per life-year or QALY) in the 39 articles (60%) in which authors supported additional expenditure, and ranged from $61,500 to $11,600,000 in the 13 articles (20%) in which authors supported the low-cost alternative. Despite identifying similar CE ratios, authors arrived at different conclusions in the overlapping range ($61,500 to $166,000). Of the 10 articles acknowledging industry funding, 9 supported a strategy requiring additional expenditure (p = .01 as compared with those without such funding).
CONCLUSIONS: Authors of CEAs are more likely to support strategies requiring additional expenditure than the low-cost alternative. There is no obvious consensus about how small the CE ratio should be to warrant additional expenditure. Finally, concerns about funding source seem to be warranted.

Mesh:

Year:  1998        PMID: 9798812      PMCID: PMC1500894          DOI: 10.1046/j.1525-1497.1998.00201.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  18 in total

1.  Oregon's methods. Did cost-effectiveness analysis fail?

Authors:  D M Eddy
Journal:  JAMA       Date:  1991-10-16       Impact factor: 56.272

2.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

Authors:  A L Hillman; J M Eisenberg; M V Pauly; B S Bloom; H Glick; B Kinosian; J S Schwartz
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

3.  The existence of publication bias and risk factors for its occurrence.

Authors:  K Dickersin
Journal:  JAMA       Date:  1990-03-09       Impact factor: 56.272

Review 4.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

Review 5.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.

Authors:  L B Russell; M R Gold; J E Siegel; N Daniels; M C Weinstein
Journal:  JAMA       Date:  1996-10-09       Impact factor: 56.272

Review 6.  Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.

Authors:  J E Siegel; M C Weinstein; L B Russell; M R Gold
Journal:  JAMA       Date:  1996 Oct 23-30       Impact factor: 56.272

7.  Use and misuse of the term "cost effective" in medicine.

Authors:  P Doubilet; M C Weinstein; B J McNeil
Journal:  N Engl J Med       Date:  1986-01-23       Impact factor: 91.245

Review 8.  A clinician's guide to cost-effectiveness analysis.

Authors:  A S Detsky; I G Naglie
Journal:  Ann Intern Med       Date:  1990-07-15       Impact factor: 25.391

9.  Cost-benefit and cost-effectiveness analysis in health care. Growth and composition of the literature.

Authors:  K E Warner; R C Hutton
Journal:  Med Care       Date:  1980-11       Impact factor: 2.983

10.  Foundations of cost-effectiveness analysis for health and medical practices.

Authors:  M C Weinstein; W B Stason
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

View more
  19 in total

1.  Economic analyses and clinical practice guidelines: why not a match made in heaven?

Authors:  Scott D Ramsey
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

Review 2.  Conflict of interest in industry-sponsored economic evaluations: real or imagined?

Authors:  M Barbieri; M F Drummond
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 3.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Authors:  Joel Lexchin; Lisa A Bero; Benjamin Djulbegovic; Otavio Clark
Journal:  BMJ       Date:  2003-05-31

4.  Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia.

Authors:  Chin Hur; Norman S Nishioka; G Scott Gazelle
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

5.  Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.

Authors:  A H Miners; Martina Garau; Dogan Fidan; A J Fischer
Journal:  BMJ       Date:  2004-12-15

Review 6.  Interpretation of cost-effectiveness analyses.

Authors:  D K Owens
Journal:  J Gen Intern Med       Date:  1998-10       Impact factor: 5.128

7.  Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs.

Authors:  Jacopo Giuliani; Andrea Bonetti
Journal:  Int J Colorectal Dis       Date:  2018-05-26       Impact factor: 2.571

8.  Cost effectiveness of foldable multifocal intraocular lenses compared to foldable monofocal intraocular lenses for cataract surgery.

Authors:  M G T Dolders; M D Nijkamp; R M M A Nuijts; B van den Borne; F Hendrikse; A Ament; W Groot
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

Review 9.  Quality-of-life assessment in rheumatoid arthritis.

Authors:  Anthony S Russell
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 10.  Preventive, predictive, and personalized medicine for effective and affordable cancer care.

Authors:  Jaak Ph Janssens; Klaus Schuster; Andreas Voss
Journal:  EPMA J       Date:  2018-03-26       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.